Fig. 1From: A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3Patient disposition. Alfa peginterferon alfa-2a, DCV daclatasvir, Lambda peginterferon Lambda-1a, mITT modified intention-to-treat, RBV ribavirinBack to article page